Vanguard Group
CVKD icon

Vanguard Group’s Cadrenal Therapeutics CVKD Stock Holding History

Vanguard Group’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$366K Sell
53,912
-327
-0.6% -$3.7K ﹤0.01% 4002
2025
Q3 		$747K Buy
54,239
+5,644
+12% +$69.9K ﹤0.01% 3859
2025
Q2 		$586K Buy
48,595
+2,962
+6% +$44K ﹤0.01% 3884
2025
Q1 		$805K Buy
+45,633
New +$839K ﹤0.01% 3775

Other funds holding CVKD

DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

Vanguard Group's CVKD Position: Q4 2025 in Review

Vanguard Group reduced its Cadrenal Therapeutics (CVKD) stake by 0.6% in Q4 2025, selling an estimated $3.7K and leaving 53,912 shares worth $366K. The position accounts for ﹤0.01% of the portfolio, ranked #4002.

Vanguard Group first reported a position in CVKD in Q1 2025 and has held it in 4 quarters since. The position peaked at $805K in Q1 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q4 2025.

  • Vanguard Group held 53,912 shares of Cadrenal Therapeutics worth $366K as of Q4 2025.
  • Vanguard Group sold 327 Cadrenal Therapeutics shares in Q4 2025, an estimated $3.7K.
  • Cadrenal Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4002 holding.
  • Vanguard Group first reported a position in Cadrenal Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Vanguard Group's Cadrenal Therapeutics position peaked at $805K in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.